Fuda Cancer Hospital
Metastases in the liver treatment cost in China typically runs from $6,200 to $10,500 for chemoembolization of the liver. Surgical options like liver resection range from $18,500 to $38,500. Total expenses depend on the cancer stage, chosen technology, and hospital tier. Patients often save 40-60% compared to the US. Top cities for these advanced oncological procedures include Guangzhou and Beijing.
Typical Metastases In The Liver Treatment Costs In China
Bookimed Expert Insight: Patients with advanced or multi-focal metastases should prioritize clinics offering specialized minimally invasive technologies. Fuda Cancer Hospital in Guangzhou is a leading choice for these complex cases. They utilize JCI-accredited protocols for NanoKnife and cryosurgery to treat tumors in difficult locations. This approach is ideal for patients who are not candidates for traditional open surgery. The facility has successfully treated over 30,000 international patients using these targeted vascular interventional therapies.
| China | Turkey | Austria | |
| Removal of liver cancer | from $21,500 | from $10,800 | from $40,000 |
| Radiofrequency ablation of the liver | from $5,500 | from $3,500 | from $12,000 |
| Liver resection | from $18,500 | from $6,000 | from $35,000 |
| Chemoembolization of the liver | from $6,200 | from $7,500 | from $16,000 |
| Chemotherapy for liver cancer | from $3,500 | from $2,800 | - |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Chinese oncology centers provide advanced Western treatments for liver metastases, focusing on minimally invasive ablation, catheter-directed therapies, and surgical resection. Accredited facilities like Fuda Cancer Hospital utilize JCI-standard protocols. These include NanoKnife and cryosurgery to target tumors while preserving healthy liver tissue.
Bookimed Expert Insight: Data from Fuda Cancer Hospital reveals a specialized focus on late-stage cases often deemed inoperable elsewhere. While many centers prioritize standard resection, Fuda utilizes a high volume of non-thermal NanoKnife procedures. This approach is specifically effective for metastases located near major blood vessels where heat-based ablation or surgery risks internal damage. This specialization has attracted patients from over 100 countries seeking alternatives for complex tumor locations.
Patient Consensus: Patients note that leading centers often propose aggressive multidisciplinary sequencing, moving quickly from systemic therapy to local interventions. Many emphasize the importance of bringing original biopsy reports and genomic results to avoid repeat testing delays.
China offers advanced non-invasive radiation options like Proton Beam Therapy through a rapidly expanding network of specialized oncology centers. Facilities in Shanghai and Guangzhou utilize high-precision particle therapy to treat complex liver metastases. These institutions maintain international standards with Joint Commission International accreditations and advanced delivery systems.
Bookimed Expert Insight: While Proton Beam Therapy is a major draw, high-volume centers like Fuda Cancer Hospital often prioritize a combination of NanoKnife and vascular interventional therapy for liver metastases. Data shows these minimally invasive techniques are frequently selected over radiation for late-stage cases. Patients should verify if a facility's 400-bed capacity includes dedicated space for international oncology recovery.
Patient Consensus: Patients note that while newer technology is attractive, doctors often recommend Stereotactic Body Radiation Therapy (SBRT) for liver lesions. They emphasize bringing complete pathology reports to ensure the tumor location actually qualifies for proton treatment.
China integrates Traditional Chinese Medicine (TCM) for liver metastases as a supportive therapy alongside Western protocols. Chinese oncology programs follow national guidelines to combine TCM with chemotherapy, immunotherapy, and interventional procedures. These integrative methods aim to optimize tolerance, support liver function, and manage treatment side effects.
Bookimed Expert Insight: While many Chinese centers provide integrative care, hospitals with JCI accreditation like Fuda Cancer Hospital emphasize specialized technologies. They utilize cryosurgery and NanoKnife for liver lesions alongside supportive interventional therapies. Leading oncologists in China, such as Professor Liu Shi Xin at Xiamen Humanity Hospital, participate in both the Chinese Medical Association and the Chinese Anti-Cancer Association. This ensures that TCM integration remains strictly under the supervision of qualified Western-trained medical experts.
Patient Consensus: Patients note that TCM helps them feel less destroyed by improving appetite and energy levels during chemo. They emphasize that measurable results come from Western medicine, while herbs serve as a practical way to manage day-to-day comfort.